Median Technologies Reports Full-Year 2025 Financial Results and Q1 2026 Highlights
Median Technologies has announced its consolidated annual financial results for 2025 along with key business highlights for the first quarter of 2026. The company focuses on AI-powered software for early cancer diagnosis and offers imaging services for oncology drug development.
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-powered and central imaging services for oncology drug developers, today reported its 2025 consolidated annual financial results, and provided key business highlights (unaudited) for the first quar